Abstract
Cutaneous T-cell lymphoma at all stages appears to be responsive to immune modulatory therapeutic approaches. We describe here the mechanistic rationale for the use of interferons, interleukin-12, retinoids, Toll-like receptor agonists, photopheresis and combinations of immune preserving, immune stimulatory therapies for CTCL.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
